Skip to content
Review

De-escalation of perioperative systemic therapy for early breast cancer.

Aug 2026 · Japanese Journal of Clinical Oncology · 0 citations
Medicine

TL;DR

Current evidence and ongoing studies on treatment de-escalation across breast cancer subtypes are summarized and integration of molecular biomarkers with response-adapted strategies may further refine risk stratification and support personalized treatment approaches.

View source

Similar papers

Review Open access Oct 2026

The evolving treatment of HER2-positive early breast cancer

HER2-positive early breast cancer (EBC) accounts for 15–20% of breast cancer cases and is characterized by aggressive biology, though outcomes have significantly improved with HER2-directed therapies. This narrative review summarizes contemporary approaches to personalize systemic treatment of HER2-positive EBC through...

C. O'Sullivan · 0 citations
Review Open access Oct 2026

The challenge of evaluating the efficacy of neoadjuvant endocrine therapy in breast cancer and potential solutions: a literature review

Hormone receptor–positive (HR+) breast cancer is the most common subtype of the disease and is characterized by significant heterogeneity in its clinical course and response to therapy. Adjuvant endocrine therapy with aromatase inhibitors represents a highly effective alternative to chemotherapy in postmenopausal patie...

M. Dzhelialova, A. V. Zolotukhina, A. Shalaev et al. · 0 citations
Review Open access Sep 2026

Novel approaches in adjuvant colorectal cancer therapy: the emerging role of exercise, aspirin, and immunotherapy

Adjuvant treatment of colorectal cancer (CRC) has traditionally been based on fluoropyrimidine- and oxaliplatin-based chemotherapy regimens, which remain the cornerstone of care for patients with resected stage III and selected high-risk stage II disease. However, despite substantial improvements in disease-free (DFS...

G. Piringer · 0 citations
Review Open access Aug 2026

Perioperative treatment for muscle invasive bladder cancer in the era of immunotherapy

Muscle-invasive bladder cancer (MIBC) remains associated with high recurrence and mortality despite radical cystectomy and cisplatin-based neoadjuvant chemotherapy (NAC). For decades, perioperative therapy was defined by platinum-based regimens, which improve survival but are limited to fewer than half of patients due...

Cheyenne Williams, Yash B. Shah, Lei-Lei Xia · 0 citations
Review Open access Oct 2026

Biomarker Integration in the Perioperative Management of Early-Stage Non-Small-Cell Lung Cancer

The concept of personalized medicine has tremendous appeal—tailoring diagnosis and treatment to an individual, rather than a “one-size-fits-all” approach. The management of non-small-cell lung cancer (NSCLC) has rapidly evolved toward strategies increasingly guided by tumor biology and precision oncology. The safety an...

Emily P. Rabinovich, Linda W. Martin · 0 citations
Review Sep 2026

Systemic therapy for metastatic nasopharyngeal carcinoma in the immunotherapy era: A critical review.

BACKGROUND The prognosis of metastatic nasopharyngeal carcinoma (mNPC) remains dismal despite recent advances of locoregional and systemic therapy. The incorporation of programmed death-1 (PD-1) inhibitors into first-line chemotherapy has transformed the therapeutic landscape; however, optimal treatment strategies beyo...

Wei-Jie Wen, Ji-Shi Li, Yuan-Mei Qu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.